$2.13
+0.23
(+12.07%)▲
7.51%
Downside
Day's Volatility :9.01%
Upside
1.62%
45.54%
Downside
52 Weeks Volatility :91.53%
Upside
84.45%
Period | Pacific Biosciences Of California, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 29.59% | 6.5% | 0.0% |
6 Months | -72.86% | 7.1% | 0.0% |
1 Year | -85.55% | 9.8% | 0.0% |
3 Years | -93.73% | 14.2% | -20.2% |
Market Capitalization | 512.0M |
Book Value | $2.38 |
Earnings Per Share (EPS) | -1.14 |
PEG Ratio | -0.17 |
Wall Street Target Price | 3.33 |
Profit Margin | -148.13% |
Operating Margin TTM | -209.82% |
Return On Assets TTM | -10.84% |
Return On Equity TTM | -44.28% |
Revenue TTM | 200.4M |
Revenue Per Share TTM | 0.77 |
Quarterly Revenue Growth YOY | -0.2% |
Gross Profit TTM | 53.5M |
EBITDA | -282.5M |
Diluted Eps TTM | -1.14 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.91 |
EPS Estimate Next Year | -0.71 |
EPS Estimate Current Quarter | -0.27 |
EPS Estimate Next Quarter | -0.25 |
What analysts predicted
Upside of 56.34%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 78.6M | ↓ 15.88% |
Net Income | -102.6M | ↑ 11.25% |
Net Profit Margin | -130.44% | ↓ 31.81% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 90.9M | ↑ 15.6% |
Net Income | -77.8M | ↓ 24.12% |
Net Profit Margin | -85.62% | ↑ 44.82% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 78.9M | ↓ 13.2% |
Net Income | 29.4M | ↓ 137.78% |
Net Profit Margin | 37.27% | ↑ 122.89% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 130.5M | ↑ 65.43% |
Net Income | -181.2M | ↓ 716.34% |
Net Profit Margin | -138.85% | ↓ 176.12% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 128.3M | ↓ 1.69% |
Net Income | -296.9M | ↑ 63.85% |
Net Profit Margin | -231.43% | ↓ 92.58% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 200.5M | ↑ 56.29% |
Net Income | -306.7M | ↑ 3.3% |
Net Profit Margin | -152.97% | ↑ 78.46% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 27.4M | ↓ 15.34% |
Net Income | -79.8M | ↓ 4.5% |
Net Profit Margin | -291.89% | ↓ 33.15% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 38.9M | ↑ 42.21% |
Net Income | -81.1M | ↑ 1.64% |
Net Profit Margin | -208.61% | ↑ 83.28% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 47.6M | ↑ 22.3% |
Net Income | -69.8M | ↓ 13.94% |
Net Profit Margin | -146.79% | ↑ 61.82% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 55.7M | ↑ 17.06% |
Net Income | -66.9M | ↓ 4.24% |
Net Profit Margin | -120.07% | ↑ 26.72% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 58.4M | ↑ 4.79% |
Net Income | -82.0M | ↑ 22.65% |
Net Profit Margin | -140.55% | ↓ 20.48% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 38.8M | ↓ 33.5% |
Net Income | -78.2M | ↓ 4.68% |
Net Profit Margin | -201.44% | ↓ 60.89% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 170.3M | ↑ 18.18% |
Total Liabilities | 56.2M | ↓ 3.05% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 148.0M | ↓ 13.09% |
Total Liabilities | 93.1M | ↑ 65.56% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 414.0M | ↑ 179.74% |
Total Liabilities | 78.5M | ↓ 15.66% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 2.0B | ↑ 384.8% |
Total Liabilities | 1.2B | ↑ 1449.24% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.8B | ↓ 11.95% |
Total Liabilities | 1.2B | ↓ 0.97% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 1.7B | ↓ 1.19% |
Total Liabilities | 1.0B | ↓ 13.24% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.8B | ↓ 2.85% |
Total Liabilities | 1.2B | ↑ 0.99% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.9B | ↑ 7.32% |
Total Liabilities | 1.2B | ↑ 0.01% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.8B | ↓ 2.57% |
Total Liabilities | 1.2B | ↑ 0.11% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.9B | ↑ 2.75% |
Total Liabilities | 1.1B | ↓ 5.89% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.7B | ↓ 8.02% |
Total Liabilities | 1.0B | ↓ 7.92% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 1.7B | ↓ 4.36% |
Total Liabilities | 1.0B | ↓ 2.28% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -66.4M | ↓ 1.61% |
Investing Cash Flow | -38.4M | ↑ 2379.99% |
Financing Cash Flow | 107.2M | ↑ 55.77% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -78.3M | ↑ 17.89% |
Investing Cash Flow | 62.0M | ↓ 261.52% |
Financing Cash Flow | 26.5M | ↓ 75.23% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 19.5M | ↓ 124.9% |
Investing Cash Flow | -219.3M | ↓ 453.48% |
Financing Cash Flow | 251.8M | ↑ 848.62% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -111.2M | ↓ 670.07% |
Investing Cash Flow | -678.5M | ↑ 209.38% |
Financing Cash Flow | 1.2B | ↑ 364.42% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -263.2M | ↑ 136.74% |
Investing Cash Flow | 116.1M | ↓ 117.11% |
Financing Cash Flow | 9.6M | ↓ 99.18% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -60.6M | ↓ 3.94% |
Investing Cash Flow | 80.4M | ↑ 49.15% |
Financing Cash Flow | 819.0K | ↓ 73.86% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -94.7M | ↑ 56.34% |
Investing Cash Flow | -72.6M | ↓ 190.24% |
Financing Cash Flow | 196.0M | ↑ 23830.28% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -41.7M | ↓ 55.92% |
Investing Cash Flow | -98.6M | ↑ 35.89% |
Financing Cash Flow | -4.7M | ↓ 102.41% |
Sell
Neutral
Buy
Pacific Biosciences Of California, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Pacific Biosciences Of California, Inc. | 40.59% | -72.86% | -85.55% | -93.73% | -63.65% |
![]() Stryker Corporation | -3.84% | 5.16% | 12.86% | 24.25% | 52.69% |
![]() Boston Scientific Corp. | -3.68% | 21.48% | 41.72% | 68.89% | 76.47% |
![]() Edwards Lifesciences Corp. | -34.8% | -18.49% | -34.85% | -45.17% | -15.86% |
![]() Abbott Laboratories | 1.03% | -5.4% | -7.12% | -11.35% | 20.75% |
![]() Medtronic Plc | -1.99% | -9.34% | -13.21% | -38.74% | -23.49% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Pacific Biosciences Of California, Inc. | NA | NA | -0.17 | -0.91 | -0.44 | -0.11 | NA | 2.38 |
![]() Stryker Corporation | 38.91 | 38.91 | 2.92 | 11.95 | 0.19 | 0.07 | 0.01 | 50.33 |
![]() Boston Scientific Corp. | 63.22 | 63.22 | 1.8 | 2.37 | 0.09 | 0.05 | NA | 13.16 |
![]() Edwards Lifesciences Corp. | 36.4 | 36.4 | 5.19 | 2.76 | 0.22 | 0.12 | NA | 12.35 |
![]() Abbott Laboratories | 33.84 | 33.84 | 5.99 | 4.66 | 0.15 | 0.06 | 0.02 | 22.31 |
![]() Medtronic Plc | 28.97 | 28.97 | 1.52 | 5.2 | 0.07 | 0.04 | 0.04 | 38.29 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Pacific Biosciences Of California, Inc. | Buy | $512.0M | -63.65% | NA | -148.13% |
![]() Stryker Corporation | Buy | $129.7B | 52.69% | 38.91 | 16.03% |
![]() Boston Scientific Corp. | Buy | $114.3B | 76.47% | 63.22 | 12.05% |
![]() Edwards Lifesciences Corp. | Buy | $52.4B | -15.86% | 36.4 | 23.74% |
![]() Abbott Laboratories | Buy | $186.6B | 20.75% | 33.84 | 13.65% |
![]() Medtronic Plc | Buy | $102.5B | -23.49% | 28.97 | 11.36% |
Insights on Pacific Biosciences Of California, Inc.
Revenue is down for the last 2 quarters, 58.35M → 38.81M (in $), with an average decrease of 33.5% per quarter
Netprofit is up for the last 2 quarters, -82.01M → -78.17M (in $), with an average increase of 4.9% per quarter
In the last 1 year, Boston Scientific Corp. has given 41.7% return, outperforming this stock by 127.2%
In the last 3 years, Boston Scientific Corp. has given 68.9% return, outperforming this stock by 162.6%
ARK Investment Management LLC
Vanguard Group Inc
BlackRock Inc
Madrone Advisors LLC
Sumitomo Mitsui Trust Holdings Inc
Nikko Asset Management Americas Inc
pacbio develops comprehensive solutions for scientists that propel the field of genomics, improve science and research, and create positive impact globally. we provide sophisticated genomic analysis systems that deliver invaluable insights for scientists who strive to resolve complex genetic challenges. our strength comes from the dedication of our people, who are fueled by a desire to effect real, positive change. with a focus on the future and an experienced, passionate team, we are motivated to continue to redefine what is possible in genomics.
Organization | Pacific Biosciences Of California, Inc. |
Employees | 796 |
CEO | Mr. Christian O. Henry M.B.A. |
Industry | Health Technology |
A Spac I Acquisition Corp
$2.13
+12.07%
Keyarch Acquisition Corp
$2.13
+12.07%
Connexa Sports Technologies Inc
$2.13
+12.07%
Us Value Etf
$2.13
+12.07%
First Wave Biopharma Inc
$2.13
+12.07%
Global X Msci Next Emerging
$2.13
+12.07%
Fat Projects Acquisition Corp
$2.13
+12.07%
Capital Link Global Fintech
$2.13
+12.07%
Applied Uv Inc
$2.13
+12.07%